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Introduction
             During the last years, the implantation rate of dual chamber defibrillators (ICD) 
significantly increased worldwide. In 1999, the proportion of dual chamber ICD implants 
reached 30% in Europe and 50% in U.S.A.1. According to manufacturer data, in Italy, the ratio 
between implanted single chamber and dual chamber units decreased from 1.97 in 1999 to 1.86 
in 2000 and 1.50 in 2001. Technological progress, demonstration of reliability and clinical 
efficacy of the new devices, combined with their smaller size, contributed to their wide 
acceptance. Nowadays, the matter to be debated is if all the patients in whom the atrium can be 
sensed and paced should receive a dual chamber ICD or if device selection should be 
individually evaluated according to different clinical profiles. As a matter of fact, criteria to 
identify the patients who may benefit more from dual chamber ICD have not been already 
defined. The theoretical advantages of dual chamber ICD include: improved discrimination 
between supraventricular  and  ventricular  tachycardias,  optimal  treatment  of  symptomatic 
bradycardias (pre-existing, drug-induced or late developing), hemodynamic and antiarrhythmic 
benefits.
Discrimination between supra-ventricular and ventricular arrhythmias                            
             Superiority of dual chamber detection algorithms versus single chamber ICD in 
discriminating supraventricular from ventricular tachycardia has been a matter of debate since 
their introduction for clinical implantation. This issue is particularly challenging if we take into 
account that the addition of enhanced criteria in the third generation single chamber ICDs, such 
as tachycardia sudden onset and stability and ventricular electrogram width and morphology, 
significantly increased single chamber ICD specificity in tachycardia discrimination2,3,4,5. On 
the other hand, the weak point of such enhanced criteria is represented by decreased sensitivity 
in ventricular tachycardia detection5,6. Dual chamber ICDs have the capability of detecting atrial 
activity and matching atrial and ventricular patterns. Clinical studies using dual chamber ICDs 
showed specificity values as high as 80-90% combined with 100% sensitivity7,8,9,10,11,12. 
Nevertheless, inappropriate detection and therapy may still happen, mainly for “difficult 
arrhythmias”. Hintringer et al13 performed a comparison of the detection algorithms of four dual 
chamber ICD when dealing with a wide spectrum of tachyarrhythmias. In spite of some 
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differences   due   the   algorithms   themselves,   typical   and   atypical   junctional   tachycardia, 
orthodromic atrio-ventricular tachycardia and 1:1 atrial flutter represented the most challenging 
patterns. As a consequence, new more sophisticated algorithms are being developed to deal with 
this task. Appropriate sensing of atrial activity, either during sinus rhythm or during atrial 
tachyarrhythmias, and appropriate rejection of ventricular activity by the atrial lead is a critical 
issue to be dealt with. Deisenhofer et al14 undertook a prospective, randomized study to compare 
the incidence of inappropriates therapies in patients treated with VVI-ICDs and DDD-ICDs. 
They enrolled 92 patients and concluded that DDD-ICD and VVI-ICD were equally safe and 
effective to treat life-threatening ventricular arrhythmias. Although DDD-ICDs theoretically 
allow better rhythm classification, the applied detection algorithms did not offer benefits in 
avoiding inappropriate therapies during supraventricular tachyarrhythmias. As a matter of fact, 
in the Deisenhofer series 75% of inappropriate therapies in the DDD-ICD group were due to 
atrial sensing problems, either oversensing or undersensing. This finding stresses the need of 
careful positioning of the atrial lead during implantation in order to combine optimal atrial 
electrogram amplitude with far field rejection. It has been suggested that positioning the atrial 
lead in the lateral atrial wall and selecting bipolar leads with short tip-to-ring distance may 
reduce far field incidence15,16. In spite of that, atrial sensing problems may intermittently appear 
during the follow-up, also when they were not present at implant or during post-implant testing. 
A possible explanation for frequent intermittent atrial sensing problems may be the special filter 
settings in the atrial sensing channels of DDD-ICD, which differs substantially from those of 
DDD pacemakers. In fact, most detection algorithms in DDD-ICDs need correct and continuous 
atrial sensing with only short or even no blanking times. This may be difficult when taking into 
account low voltage atrial electrogram during atrial fibrillation and large ventricular far fields 
during paced ventricular beats.                                                                                   
Hemodynamic   issues                                                                                      
            A emerging key point in debating optimal device selection is represented by the impact 
of   single   chamber   and   dual   chamber   ICD   implantation   on   hemodynamics.
            It has been demonstrated that, in patients with sinus bradycardia and/or atrio-ventricular 
conduction disturbances, physiologic pacing by sequential dual chamber stimulation and 
optimized, individually programmed, atrio-ventricular delay may offer major improvement in 
hemodynamics and clinical outcome, mainly when heart failure coexists17,18,19. On the other 
hand, during the last years it has been demonstrated that asynchronous ventricular activation 
induced   by   apical   right   ventricular   pacing   may   induce   major   interventricular   and/or 
intraventricular dysynchrony, which may deteriorate hemodynamics and impair myocardial 
metabolism20,21. Isovolumic contraction time and isovolumic relaxation time lenghtening may 
critically shorten diastolic filling, impairing cardiac output. Furthermore, delayed activation of 
the left ventricular lateral wall may lead to late contraction which happens after aortic valve 
closure, so that not only it does not contribute to stroke volume, but also impair diastolic 
filling22.
            Concern about the potential deleterious effect of unnecessary right ventricular pacing in 
ICD population is even greater than in pacemaker patients, when considering the higher 
prevalence   of   heart   failure   and   left   ventricular   dysfunction   in   patients   who   need   ICD 
implantation23,24. The recently published DAVID25  (Dual Chamber and VVI Implantable 
Defibrillator) Trial dealt with this issue. Objective of the study was to determine the efficacy of 
dual chamber pacing compared with backup ventricular pacing in patients with standard 
indications for ICD implantation but without indications for antibradycardia pacing. The design 
of the study was a single-blind, parallel group, randomized, multicenter clinical trial. Five 
hundred and six patients candidates for ICD with left ventricular ejection fraction of 40% or 
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less, no indications for antibradycardia pacing and no persistent atrial tachyarrhythmias, 
received a dual chamber ICD and were randomly assigned to have the ICD programmed to 
ventricular back-up pacing at 40/min or to dual chamber rate responsive pacing at 70/min. Main 
outcome measurement was the combined end point of time to death or first hospitalization for 
congestive heart failure. The study was early stopped by the Data and Safety Monitoring Board 
because the conditional power for the original alternative (DDDR-70 being better than VVI-40) 
was less than 10%. The VVI-40 group had fewer occurrences of the composite end point than 
DDD-70 group: one-year survival free was 83.9% versus 73.3% (relative hazard 1.61; 95% 
confidence interval 1.06-2.44, p< 0.03). Although the VVI-40 patients had fewer events, the 
component end points, either death or heart failure hospitalizations, did not individually reach 
statistical  significance.                                                                                          
            Some criticisms have been pointed out about the DAVID Trial. The study definitely 
demonstrated that right ventricular pacing is deleterious in patients with left ventricular 
dysfunction, but it cannot be concluded that single chamber ICD with back-up ventricular 
pacing is the most useful device for patients with heart failure. In spite of a large enrolled 
population, the follow-up was very short because of early stopping of the study. Only a minority 
of patients completed one year follow-up. Programming dual chamber rate responsive pacing at 
70/min without long AV delay does not seem the best choice for patients without any indication 
for antibradycardia pacing. Unnecessary apical right ventricular pacing is probably the key to 
explain the higher event rates in DDD-70 arm. The Authors stressed that dual chamber pacing 
could be beneficial in heart failure patients since it may allow a wider use of drugs such as beta 
blockers which depress sinus and AV node function. As a matter of fact, there were no 
differences in drug regimen between the VVI and DDD arms after randomization as well as after 
6-month follow-up. Finally, patients with atrial tachyarrhythmias were excluded from the study, 
so introducing a limitation in the clinical value of the study.                                    
Atrial fibrillation in  ICD patients                                                                       
            Atrial fibrillation prevention and early treatment by dual chamber devices, mainly if 
equipped with atrial antitachycardia functions, may represent a major benefit in patients with 
heart failure. ICD patients actually show a high incidence of atrial tachyarrhythmias. It has been 
reported that 20% of them had atrial fibrillation before implantation and that during the life-span 
of the defibrillator more than 50% may develop atrial fibrillation26. Atrial fibrillation may lead 
to   inappropriate   ventricular   shocks27,   ventricular   arrhythmia   induction28,   may   impair 
hemodynamics and induce thromboembolic events or acute myocardial infarction, and has been 
identified as an individual predictor of poor prognosis29,30. Atrial antitachycardia functions 
available in some last generation dual chamber ICDs (pacing prevention algorithms and 
antitachycardia pacing) have been demonstrated to be effective in preventing and early treating 
atrial tachyarrhythmias. In our own experience31, related to 112 patients receiving an ICD 
because of life threatening ventricular arrhythmias, followed on average for 1 year, anti-tachy-
pacing efficacy was as high as 71% on atrial tachycardia and as 36% on atrial fibrillation. Shock 
success rate was 92% when delivered energy was adequately programmed, which means at least 
twice the atrial defibrillation threshold at implant. Similar results have been reported by 
others32. The impact of atrial prevention algorithms and atrial therapies on atrial fibrillation 
burden has been investigated by Friedman and coworkers33. They designed a study in which 
atrial fibrillation prevention and termination therapies were randomly programmed “on” or “off” 
for three months and then crossed over to the opposite arm for an additional 3 months. Fifty-two 
patients were studied. During the “on” period the arrhythmia burden (hours/month) significantly 
decreased: the mean burden from 58.5 to 7.8 and the median burden from 2.82 to 0.63. The 
mean burden reduction was 87%. The reduction in arrhythmia burden during the “on” period 
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could be demonstrated also in the subgroup of patients (forty-one) in whom no shocks were 
delivered and only antitachy pacing therapies were applied.                                                           
            Considering the major clinical impact of symptomatic atrial fibrillation in patients who 
are candidate for defibrillator implantation, a device equipped with atrial antitachycardia 
facilities may improve clinical outcome, by preventing acute heart failure, by decreasing 
inappropriate   shocks,   by   reducing   hospitalizations   and   by   improving   quality   of   life.
Perspectives
            The key point for single chamber or dual chamber ICD selection has been progressively 
switching from optimal tachycardia discrimination to the impact on hemodynamics and on atrial 
arrhythmia   control.   To   this   regard,   few   controlled   data   are   available   and   perspectives 
randomized trials are strongly needed. The impact of device selection on the overall clinical 
outcome is the target of an ongoing trial [Dual Chamber & Atrial Tachyarrhythmias Adverse 
Events Study (DATAS), protocol in press34] aimed at comparing clinical benefits of dual 
chamber ICD with atrial antitachycardia functions with single chamber ICD. The primary end 
point will be the composite end-point resulting from all-causes mortality, invasive intervention, 
hospitalizations due to cardiovascular cause, inappropriate shocks and sustained symptomatic 
atrial tachyarrhythmias. The enrollment is going to be completed soon and the results will be 
available within the next two years.                                                                             
             On the other hand, new indications for ICD implantation in primary prevention of 
sudden   death   and   introduction   of   triple   chamber   ICDs   capable   of   delivering   cardiac 
resynchronization therapy are going to change very soon the whole approach to ICD selection. 
The MADIT-2 trial35 demonstrated that in patients with prior myocardial infarction and left 
ventricular ejection fraction < 30%, ICD implantion was able to reduce 2-year mortality by 31%. 
Rules for ICD selection in MADIT-2 patients are probably quite different from those applied for 
patients receiving an ICD in sudden death secondary prevention. A wider use of single chamber 
ICDs   should   be   expected.   First,   accurate   discrimination   between   supraventricular   and 
ventricular tachycardia should be less meaningful in patients for whom therapy programming is 
focused mainly on treating fast ventricular tachycardia and ventricular fibrillation. Secondly, 
considering the large number of new potential candidates for ICD implantation, selecting a 
simpler and less costly device may improve the cost-effectiveness of ICD in primary prevention. 
Development of new low-cost single chamber devices, just capable of detecting ventricular 
fibrillation and delivering a limited number of shocks is expected for the next years. Such 
strategy will allow a wider protection of high risk population without an unacceptable increasing 
of   the   costs.                                                                                  
            Cardiac resynchronization has been demonstrated to improve functional class, exercise 
tolerance and quality of life as well as to reduce hospitalisations due to worsening of heart 
failure36,37 in patients with drug refractory heart failure with atrio-ventricular, inter-ventricular 
and intra-ventricular dysynchrony. Cardiac resynchronization may be combined with ICD. 
Considering the large number of ICD candidates with heart failure, drawing guidelines aimed to 
make the right choice for individual patients will be a major challenge for the next few years.
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